Centrally acting antihypertensive drugs. Present and future

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Neuroscience

Background:

• Centrally acting antihypertensives like clonidine and alpha-methyl-DOPA target alpha2-adrenoceptors in the brain stem, leading to reduced blood pressure.
• These older agents often cause significant side effects (e.g., sedation, dry mouth) due to broader alpha2-adrenoceptor interactions.
• A new class of antihypertensives, including moxonidine and rilmenidine, acts on imidazoline I1-receptors in the rostral ventromedulla.

Purpose of the Study:

• To survey the mode of action, hemodynamic profile, and antihypertensive efficacy of both classic and newer centrally acting antihypertensives.
• To compare the adverse reaction profiles of these drug classes.
• To explore additional therapeutic applications beyond hypertension, such as congestive heart failure and metabolic syndrome.

Main Methods:

• Review of existing literature on centrally acting antihypertensives.
• Analysis of pharmacological mechanisms, including receptor affinities (alpha2-adrenoceptors and imidazoline I1-receptors).
• Comparison of clinical data regarding efficacy, hemodynamic effects, and adverse events.

Main Results:

• Classic antihypertensives (clonidine, alpha-methyl-DOPA) act via alpha2-adrenoceptor stimulation, causing sympathoinhibition but also notable side effects.
• Newer agents (moxonidine, rilmenidine) primarily target imidazoline I1-receptors, achieving sympathoinhibition with a potentially better side-effect profile.
• The improved tolerability of newer agents may stem from their weaker affinity for alpha2-adrenoceptors.

Conclusions:

• Imidazoline I1-receptor agonists represent a promising alternative to older alpha2-adrenoceptor agonists for managing hypertension.
• These newer agents may offer a more favorable therapeutic index due to reduced side effects.
• Further investigation into their utility for conditions like heart failure and metabolic syndrome is warranted.